中医药防治肺癌及呼吸系统疾病Prevention and treatment of lung cancer and respiratory diseases with traditional Chinese medicine
王丽新，医学博士，主任医师，教授，博士生导师，同济大学附属上海市肺科医院中西结合科行政主任，党支部书记，内科教研室副主任。美国西奈山医学院Mount Sinai Medical Centre访问学者。
Wang Lixin, MD, Chief Physician, Professor, Doctoral Supervisor, Administrative Director of the Department of Combination of Chinese and Western Medicine, Shanghai Pulmonary Hospital affiliated to Tongji University, Party Branch Secretary, Deputy Director of Internal Medicine Teaching and Research Section. Visiting Scholar, Mount Sinai Medical School, USA.
Vice President of China Future Research Association-Chinese Medicine Integration Branch,
Vice chairman of oncology branch of shanghai traditional medical engineering association,
Executive Director of the Committee on Precision Oncology Medicine of the World Society of Traditional Chinese Medicine,
Executive Director of CSCO Cancer Branch of Integrated Traditional Chinese and Western Medicine,
National Natural Science Foundation of China Online Review Expert, Shanghai Municipal Science and Technology Commission Review Expert
近五年来先后主持和参与国家重点研究计划、国家自然科学基金、上海市科委创新引导项目、上海市申康中心临床创新项目、上海市教委、上海市三年行动计划等10余项课题研究，累计科研经费300余万元。先后受上海中医药大学后备业务专家、上海市科委白玉兰人才项目资助。主要研究论文30余篇， SCI影响因子30余分， 获得上海市中医药科技二等奖，获得发明专利2项，执笔CSCO专家共识。长期从事肺癌免疫与肺癌精准治疗的临床和转化研究，在延缓肺癌靶向耐药、提高肺癌术后无病生存期、预防复发和转移方面具有明显优势。同时聚焦中医药小分子化合物的筛选，探讨其抗肿瘤免疫机制。
In the past five years, she has presided over and participated in more than 10 research projects, including the National Key Research Program, the National Natural Science Foundation, the Innovation Guidance Project of the Shanghai Municipal Science and Technology Commission, the Clinical Innovation Project of the Shanghai Shenkang Center, the Shanghai Municipal Education Commission, and the Shanghai Three-year Action Plan, with a cumulative scientific research funding of more than 300 million yuan. It has been supported by the reserve business experts of Shanghai University of Traditional Chinese Medicine and the Magnolia talent project of Shanghai Science and Technology Commission. There are more than 30 major research papers, with SCI impact factor of more than 30 points. It won the second prize of Shanghai Traditional Chinese Medicine Science and Technology Award, won 2 invention patents, and wrote the consensus of CSCO experts. She has long been engaged in clinical and translational research on lung cancer immunity and precision treatment of lung cancer, and has obvious advantages in delaying targeted drug resistance of lung cancer, improving disease-free survival after lung cancer surgery, and preventing recurrence and metastasis. At the same time, focus on the screening of small molecule compounds of traditional Chinese medicine to explore its anti-tumor immune mechanism.